



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/116319/>

Version: Accepted Version

Article:

Eyre, DW, Dingle, KE, Didelot, X et al. (2017) Clostridium difficile in England: can we stop washing our hands? – Authors' reply. *Lancet Infectious Diseases*, 17 (5). pp. 478-479.
ISSN: 1473-3099

[https://doi.org/10.1016/S1473-3099\(17\)30185-8](https://doi.org/10.1016/S1473-3099(17)30185-8)

© 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International <http://creativecommons.org/licenses/by-nc-nd/4.0/>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Due date 24th March.

CORRESPONDENCE

Authors' reply to:

English *C. difficile* - can we stop hospital infection control (THELANCETID-D-17-00215)

Authors:

David W. Eyre, DPhil., Kate E. Dingle, Ph.D.*, Xavier Didelot, D.Phil., T. Phuong Quan, MSc., Timothy E.A. Peto, D.Phil., Mark H. Wilcox, M.D., A. Sarah Walker, Ph.D., and Derrick W. Crook, M.B.B.Ch.

*Corresponding author, tel: +44 1865 220870; fax: +44 1865 764192; email:

kate.dingle@ndcls.ox.ac.uk

Nuffield Department of Clinical Medicine, Oxford University, UK (K.E.D., T.P.Q., D.W.E., T.E.P., A.S.W., D.W.C.)

National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK (K.E.D., T.P.Q., D.W.E., T.E.P., A.S.W., D.W.C.)

NIHR Oxford Health Protection Research Unit on Healthcare Associated Infection and Antimicrobial Resistance (K.E.D., T.P.Q., S.H., A.P.J., T.E.P., A.S.W., D.W.C.)

Department of Infectious Disease Epidemiology, Imperial College, London, UK and NIHR Imperial Health Protection Research Unit on Healthcare Associated Infection and Antimicrobial Resistance (X.D.)

Leeds Teaching Hospitals and University of Leeds, Department of Microbiology, Leeds General Infirmary, Leeds, UK (M.H.W.),

Here, mathematical modelling shows that hospital infection control (HIC) interventions can preferentially reduce hospital-adapted strains over community-adapted strains within and outside hospitals, questioning our conclusion that restrictions in fluoroquinolone use were responsible for most of the decline in *C. difficile* infection (CDI).¹ “All models are wrong, but some are useful” [George Box]. The key is not whether a model can reproduce findings from an empirical study, but whether its underpinning assumptions are sufficiently plausible. Unfortunately, several features are implausible in this model, which seems more appropriate to MRSA.

Firstly fluoroquinolone-resistant strains are assumed to be hospital-adapted, i.e. transmit more efficiently in hospital, and, crucially, fluoroquinolone-susceptible strains are assumed community-adapted. The former is possible, since *C. difficile* transmission may be promoted, at least partly, by resistance itself. But why the latter should hold is unclear, particularly as most fluoroquinolone use in our study was in the community. Additionally, if resistance itself confers hospital-adaptation, reducing fluoroquinolone use would be expected to reduce hospital-adaptation; this is not considered in the model.

The second assumption is competition between fluoroquinolone-resistant and fluoroquinolone-susceptible *C. difficile*, i.e. infection by one precludes the other. This is required for the incidence of susceptible strains to remain unchanged despite HIC interventions. However, as acknowledged, this is a simplification; rates of CDI with multiple genotypes are ~7%.² Third, the model’s parameters produce implausibly high *C. difficile*

prevalence (>20%/10% in hospital/community), contradicting empirical observations (typically $\leq 10\%$ and $\sim 4\%$, respectively).³ Both exaggerate competition in the model.

Fourth, the model assumes that bacteria are transmitted in hospitals exclusively via healthcare workers (HCW). Whilst patient-to-patient transmission is modelled in the community, it is not within hospitals, and no contribution from the environment or other reservoirs is allowed. This clearly substantially amplifies the effect of any HCW intervention.

Fifth, the model considers only asymptomatic colonisation, which is never treated, so the mean 200-day carriage duration of resistant-bacteria, regardless of location, may be reasonable. However, for unclear reasons, susceptible-bacteria are assumed to be lost 3.3-fold faster in hospital than resistant-bacteria, but at the same rate in the community.

Infections are not directly modelled, despite CDI symptoms being a key determinant of transmission (in contrast with MRSA).⁴ Instead, the model assumes 1 in 10 colonisations result in symptomatic infections; these would be treated, and the vast majority of fluoroquinolone-susceptible and fluoroquinolone-resistant isolates are equally susceptible to first-line CDI therapy (metronidazole/vancomycin), giving no advantage to either.

The authors raise an intriguing question that merits careful consideration across a range of healthcare-associated infections. We would welcome the opportunity to work with them to explore the performance of their model under realistic assumptions for *C. difficile*; particularly to explore why stewardship interventions may achieve CDI control despite prior multi-factorial HIC measures not doing so,⁵ and why reductions in CDI have not occurred in North America, despite similar HIC interventions, but without fluoroquinolone restriction.

References

- 1 Dingle KE, Didelot X, Quan TP, *et al.* Effects of control interventions on *Clostridium difficile* infection in England: an observational study. *Lancet Infect Dis* 2017; **0**. DOI:10.1016/S1473-3099(16)30514-X.
- 2 Eyre DW, Walker AS, Griffiths D, *et al.* *Clostridium difficile* Mixed Infection and Reinfection. *J Clin Microbiol* 2012; **50**: 142–4.
- 3 Loo VG, Bourgault A-M, Poirier L, *et al.* Host and pathogen factors for *Clostridium difficile* infection and colonization. *N Engl J Med* 2011; **365**: 1693–703.
- 4 Mawer DP, Eyre DW, Griffiths D, *et al.* Contribution to *Clostridium difficile* transmission of symptomatic patients with toxigenic strains who are fecal toxin negative. *Clin Infect Dis* 2017; published online Feb 3. DOI:10.1093/cid/cix079.
- 5 Valiquette L, Cossette B, Garant M-P, Diab H, Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of *Clostridium difficile*-associated disease caused by the hypervirulent NAP1/027 strain. *Clin Infect Dis* 2007; **45 Suppl 2**: S112–21.